• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day

    9/10/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness on a global scale.
    • Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom's 2025 World Diabetes Day campaign.

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910746857/en/

    Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom's 2025 World Diabetes Day campaign.

    Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom's 2025 World Diabetes Day campaign.

    Now through Sept. 19, people from 2 years and older living with all types of diabetes and prediabetes – including Dexcom Warriors* and Stelo ambassadors† – can apply at Dexcom.com/WorldDiabetesDay. Those selected will embody strength, advocacy and pride living with diabetes.

    "We've long believed that real people with diabetes should be the voice of our company, and we've fostered that belief through our global Dexcom Warrior and Stelo Ambassador communities," said Anne Santoro, senior vice president, product marketing at Dexcom. "Now, we're giving these communities – and anyone living with diabetes who's passionate about raising awareness – a chance to share their voice on a global stage."

    Those selected will receive an invite to participate in a photoshoot in Los Angeles to have their unique and inspiring story featured in Dexcom's 2025 World Diabetes Day campaign. They'll also have ongoing support from Dexcom over the next year to attend events, connect with the diabetes community and continue to advocate for diabetes awareness.

    "I never sought to be the face of diabetes advocacy – I just wanted to share my story and hope that it would connect with people," said Nick Jonas, American multi-platinum recording artist, songwriter, actor and philanthropist. "Over the years, I've learned that using our voices to spread messages of support, hope and perseverance can have a major impact on people's lives, so I'm proud to support this open call and see Dexcom empower people with diabetes to do even more incredible work in their communities."

    To nominate yourself or someone you know, visit Dexcom.com/WorldDiabetesDay. Nominations close Sept. 19 at 12 p.m. PDT.

    About Dexcom

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    *

    Dexcom G-Series products are indicated for individuals with T1, T2 or Gestational Diabetes ages 2 years and older

    †

    Stelo is cleared by the FDA for adults not on insulin who are 18 or older* in the United States

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250910746857/en/

    Media Contact

    James McIntosh

    [email protected]



    Investor Contact

    Sean Christensen

    [email protected]

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    12/2/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    11/25/2025$68.00In-line
    Evercore ISI
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    More analyst ratings

    $DXCM
    SEC Filings

    View All

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    1/12/26 7:30:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    12/22/25 4:35:12 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    11/12/25 10:52:52 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

    DexCom, Inc. (NASDAQ:DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the fourth quarter of 2024. U.S. revenue is expected to be approximately $892 million, representing growth of 11% over the fourth quarter of 2024. International revenue is expected to be approximately $368 million, an increase of 18% over the fourth quarter of 2024. For fiscal 2025, total preliminary, unaudited revenue is approximately $4.662 billion, an increase of 16% over 2024. In conjunction with the preliminary fourth quarter results, the company is also reiterating 2025 non-GAAP gross profi

    1/12/26 7:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer

    Mr. Leach begins his inaugural year as CEO with speaking engagements at CES 2026 and the 44th annual J.P. Morgan Healthcare Conference A completely reimagined Stelo app experience will launch this year, further advancing personalized health technology for consumers interested in metabolic health With continued investments across its portfolio, including the pharmacy launch of Dexcom G7 15 Day and AI-driven enhanced features, Dexcom is poised to transform even more lives through its glucose biosensing technology in 2026 DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, customer-driven innovation under the leadership

    1/7/26 9:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

    New personalised learning platform aims to build confidence in healthcare professional (HCP) CGM knowledge, no matter their previous experience, and support high-quality diabetes care. Designed with HCPs for HCPs. Available as a mobile app to fit with busy HCP schedules. Now available in five countries with further expansion planned across Europe, the Middle East, and Africa (EMEA). DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now ava

    12/4/25 8:02:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Collins Richard Alexander sold $171,599 worth of shares (2,906 units at $59.05) (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/17/25 5:52:36 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Heller Bridgette P sold $58,767 worth of shares (1,012 units at $58.07), decreasing direct ownership by 4% to 27,031 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/12/25 5:14:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dexcom upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Dexcom from Equal-Weight to Overweight and set a new price target of $75.00

    12/2/25 8:17:55 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Dexcom with a new price target

    Evercore ISI initiated coverage of Dexcom with a rating of In-line and set a new price target of $68.00

    11/25/25 8:40:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Dexcom with a new price target

    Stifel resumed coverage of Dexcom with a rating of Buy and set a new price target of $85.00

    10/21/25 7:19:41 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

    DexCom, Inc. (NASDAQ:DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the fourth quarter of 2024. U.S. revenue is expected to be approximately $892 million, representing growth of 11% over the fourth quarter of 2024. International revenue is expected to be approximately $368 million, an increase of 18% over the fourth quarter of 2024. For fiscal 2025, total preliminary, unaudited revenue is approximately $4.662 billion, an increase of 16% over 2024. In conjunction with the preliminary fourth quarter results, the company is also reiterating 2025 non-GAAP gross profi

    1/12/26 7:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

    10/2/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care